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Background: Tapentadol is a novel centrally acting analgesic. There is no method for the determination of drug
content in dosage form without any interference of any excipients and without using the diethylamine content in
the mobile phase with UV detection.
Methods: A simple, precise, and accurate new reverse-phase high-performance liquid chromatography (RP-HPLC)
method was developed and validated as per International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use guidelines to determine tapentadol hydrochloride in tablet
dosage form. It was successfully eluted at 5.34 min by mixture of 0.1% formic acid in water and acetonitrile (75:25)
on C18 column (250 mm × 4.6 mm, 5 μm) at the flow of 1 ml/min.
Results: Drug content was determined in between 99.79% and 100.33% with standard deviation of 0.217 without
using dimethylamine with UV detection.
Conclusions: The validated RP-HPLC method may be successfully applied for assay, dissolution studies, bio-
equivalence studies, as well as routine analysis in pharmaceutical industries.
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Tapentadol (TAP), chemically 3-[(1R,2R)-3-(dimethyl-
amino)-1-ethyl-2-methylpropyl]phenol (Figure 1), is a no-
vel centrally acting analgesic with a dual mode of action:
μ-opioid receptor agonism and noradrenaline reuptake in-
hibition. This combination of dual action effect not
only provides effective analgesia in a broad range of
acute and chronic pain conditions but also provides an
‘opioid-sparing’ effect, i.e., to lower the dose of TAP
required to produce a given level of analgesia. TAP
also exerted analgesic effects in patients undergoing
moderate-to-acute, inflammatory, and chronic neuro-
pathic pain (Schneider et al. 2010; Vadivelu et al. 2011;
Wade and Spruill 2009). However, in veterinary practice, its
use is still uncertain and controversial (Giorgi 2012a). Re-
cently, a comprehensive review on tapentadol counting the* Correspondence: pawanbasniwal@gmail.com
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reproduction in any medium, provided the origrecent trends in synthesis, related substances, analytical
methods, pharmacodynamics, and pharmacokinetics has
been published (Jain and Basniwal 2013).
Only few studies were conducted to determine TAP, viz.
in urine (Coulter et al. 2010), in urine and oral fluid
(Bourland et al. 2010) by liquid chromatography-mass
spectrometry (LC-MS), and in canine plasma by high-
performance liquid chromatography (HPLC) with
spectrofluorimetric detection (Giorgi et al. 2012b) and
pharmacokinetic studies in dogs (Giorgi et al. 2012c).
UV detection was performed in most pharmaceutical
industries, while spectrofluorimetric detector is not
widely applicable. Longer saturation time is needed
when amino derivative (diethylamine or triethylamine)
modifier is used as a component of mobile, which is not
recommended for routine analysis of drug content in
the pharmaceutical industry. It also causes bonus trou-
bles during analysis such as erratic baselines and poor
peak shape (Synder et al. 1997). In this context, very
complex mobile phases were used for the separation ofis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Structure of tapentadol hydrochloride.
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(Marathe et al. 2013), potassium dihydrogen ortho-
phosphate and potassium hydroxide (Kathirvel et al.
2013), and phosphate buffer with glacial acetic acid
and triethylamine (Sherikar and Mehta 2012). As we
have experienced, the working range for HPLC
methods is near 10 μg/ml, while the mentioned phases
have very high working ranges at 75 to 300 μg/ml
(Kathirvel et al. 2013) and 5 to 100 μg/ml (Sherikar
and Mehta 2012).
Thus, there is still a gap in research work; there is no
method for the determination of TAP in dosage form,
which claims that there is no interference of any excipi-
ents in determination without using complex mobile
phase and with higher sensitivity. The new reverse-
phase HPLC (RP-HPLC) method was developed and
validated as per International Conference on Harmon-
isation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) guidelines with-
out using diethylamine content in the mobile phase
with DAD detection, which is simple, rapid, precise,




The HPLC chromatograph used was Agilent Infinity 1260
series (Agilent Technologies, Santa Clara, CA, USA)
equipped with a 1260 binary pump VL (400 bar), 1260
manual injector (600 bar), Rheodyne 7725i seven-port sam-
ple injection valve with a 20-μl fixed loop, ZORBAX Eclipse
Plus C18 (250 mm × 4.6 mm, 5 μm), 1260 DAD VL, 20-Hz
detector, a standard flow cell (10 mm, 13 μl, and 120 bar;
OpenLab CDS EZChrom Ed. Workstation), and 50-μl syr-
inge (FN, LC tip). All weighing for analysis was performed
on a Shimadzu electronic analytical balance AX-200 (Kyoto,
Japan). Water used for analysis was prepared by triple distil-
lation assembly. All dilutions, mobile phase and other solu-
tions, used for the analysis were filtered through a 0.2-μm
nylon filter (Ultipor®N66 Nylon 6,6 membrane, Pall Sci-
ences, Pall India Pvt. Ltd. Mumbai, India).Chemicals and reagent
The working standard used was TAP which was supplied
by Ranbaxy Laboratories Limited, Gurgaon, Harayana,
as a gift sample. Tablets of TAP (TRANSDOL 50, Lupin
Ltd. Mumbai, India) were procured from the local mar-
ket. Triple distilled water was prepared from distillation
assembly. Formic acid and acetonitrile were procured
from Merck Specialties Private Limited Mumbai, India.
The mobile phase was prepared from the combination
of formic acid (0.1%) and acetonitrile.
Sample preparation
Accurately weighed 50 mg of TAP was dissolved in triple
distilled water to prepare stock I (1,000 μg/ml) in 50-ml
volumetric flask. Stock II (100 μg/ml) was prepared
from stock I, which was used to prepare further dilu-
tions containing 0.2, 0.4, 0.8, 1.2, 1.6, and 2 μg/ml. All
dilutions were filtered through 0.2-μm nylon filter
(Ultipor®N66 Nylon 6,6 membranes, Pall Sciences).
Chromatography
The filtered dilutions were chromatographed by the set of
conditions on Agilent Infinity 1260 series. The mixture of
0.1% formic acid and acetonitrile (75:25) was used as mo-
bile phase for the elution of the drug on ZORBAX Eclipse
Plus C18 column (250 mm × 4.6 mm, 5 μm) at 1 ml/min
of flow rate. TAP was successfully eluted at 5.8 min with a
run time of 7 min, and detection was performed by photo-
diode array detector (PDA) at 272 nm.
Method validation
According to the ICH guidelines (ICH Q2A 1994; ICH
Q2B 1996), the developed method was validated to assure
the reliability of the results of analysis for different param-
eters viz. linearity, range, accuracy, precision, robustness,
ruggedness, limit of quantization (LOQ), limit of detection
(LOD), and specificity. Linearity was determined by serial
dilutions (0.2 to 2 μg/ml) of the TAP in distilled water in
triplicates. The range of TAP was validated between 0.8
and 1.6 μg/ml with triplicates of dilutions. Accuracy was
determined by recovery method by spiking the standard
solution to the pre-analyzed samples. This procedure was
repeated six times. Precision of the method was studied
under the head of repeatability and intermediate precision.
The six replicates of 0.8 μg/ml were chromatographed
subsequently to assure the repeatability. Intermediate pre-
cision was determined by day-to-day analysis variation
and analyst-to-analyst variation in the linearity range.
Robustness of the method was studied with variation in
temperature (20°C, 25°C, and 30°C) and content of formic
acid (0.1%) in aqueous phase variation by a 5% change.
Serial dilutions of TAP from 1 to 1,000 ng/ml were chro-
matographed, which was repeated three times to deter-
mine LOD and LOQ. Specificity was ascertained by
Figure 2 Counter plot (A) and chromatogram (B) of TAP. TAP is in 0.1% formic acid and acetonitrile (75:25) at 5.34 min.
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lution stability was demonstrated by analyzing six repli-
cates of 0.8 μg/ml TAP standard samples at different time
intervals (0, 12, 24, 36, and 48 h) with freshly prepared
mobile phase on each time.Figure 3 Three-dimensional view of chromatogram of TAP in 0.1% foAnalysis of dosage form
Powdered tablets were weighed equivalent to 50 mg of
TAP and sonicated to dissolve drug content in triple dis-
tilled water. The sonicated solution was filtered through
Whatman filter (no. 41), and different serial dilutions werermic acid and acetonitrile (75:25) at 5.34 min.
Figure 4 Spectrum of TAP at 5.34 min in 0.1% formic acid and acetonitrile (75:25).
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The dilutions were chromatographed, and percentages of
drug content in tablets were determined by extrapolating
the AUC values on regression line.
Results and discussion
Optimization of chromatography
The RP-HPLC method was optimized with the objective
of developing a simple, precise, accurate, and fast assay
method for TAP. On the basis of chemistry and solubility
of TAP, the initial mixture of water and acetonitrile (50:50)
was made to elute TAP on C18 column (250 mm × 4.6
mm, 5 μm) at the flow of 1 ml/min. The splitting of peak
was observed, which indicates that the drug ionizes in the
present mobile phase and the peak was highly broadened.
Now, the pKa values (9.34 and 10.45) of the TAP have
been taken into consideration to design the mobile phase
(Synder et al. 1997), so the acidic pH should be favored to
elute the drug in a single peak with an acceptable peak
shape because in acidic pH, it should be present inFigure 5 Peak purity curve of TAP at 5.34 min in 0.1% formic acid annonionic form. Formic acid (0.1%) in water and aceto-
nitrile (50:50) was run to elute TAP. The drug was eluted
with a diluent peak which was splitting in nature. When
aqueous content was decreased, more splitting was ob-
served with diluent peaks, i.e., acidic content in the mobile
phase should be increased. Thus, aqueous phase (acidic
content) was increased to 70%; the single peak without
splitting was observed which was near the diluent peak
with acceptable peak shape but with tailing. Finally, TAP
was better resolved from the diluent peak without splitting
with acceptable peak shape (no tailing and fronting) in 0.1%
formic acid in water and acetonitrile (75:25). Thus, we have
excluded the use of amino derivative (diethylamine or
triethylamine) as modifier of the mobile phase.
It was clearly shown in Figure 2A,B that the diluent peak
comes in between 2.5 and 3.5 min and is well resolved
from the TAP peak (5.34 min). Three-dimensional view
(Figure 3) of the chromatogram also confirmed that there
was no peak around the TAP elution time. The above mo-
bile phase composition enabled the peak shape andd acetonitrile (75:25).
Table 2 Validation parameters of RP-HPLC method for TAP
Parameters Valuesa ± SD, ± %RSD
Linearity 0.2 to 2 μg/ml
Regression equation AUC = 18,374.93× −62.59
Correlation coefficient r2 = 0.9998 ± 0.001, ± 0.100
Response ratio 2,377.778 ± 1.510, ± 0.063
Range 0.8 to 1.6 μg/ml ± 1.23, ± 0.02
Accuracy 100.05 ± 0.841, ± 0.841
Precision
Repeatability 100.07 ± 0.319, ± 0.319
Intermediate precision
Inter-day 99.89 ± 0.205, ± 0.205
Analyst to analyst 99.74 ± 0.125, ± 0.125
Robustness
Temperature (20°C, 25°C, 30°C) 100.21 ± 0.75, ± 0.748
Formic acid concentration (±5%) 100.12 ± 0.54, ± 0.539
LOQ 8 ng/ml ± 0.93, ± 0.063
LOD 1 ng/ml ± 0.78, ± 0.067
Specificity Ascertained by analyzing
standard drug and samples
of equivalent concentration
Stability in sample solution
Response ratio 184.16 ± 1.83, ± 0.057
LOD limit of detection, LOQ limit of quantization. aMean of six replicates.
Table 3 Result of assay of TAP dosage form
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tector has good spectra of the drug. The detection
wavelength was confirmed at 272 nm by the spectrum
of TAP at an elution time of 5.34 min (Figure 4), while
previously reported methods have different detection,
viz. spectrofluorimetric and LC-MS methods, which
were costly than UV detection. The peak purity curve at
the elution time of the TAP (Figure 5) indicated that
there was no interference with the peak of TAP as the
peak purity of the TAP was one unit.
System suitability parameters
System suitability parameters were analyzed to check the
system performance consistency. For system suitability
parameters, six replicates of high quality control sample
of TAP was injected, and column performances like tail-
ing factor, retention time, and number of theoretical
plates were observed (Table 1); values of percentage of
relative standard deviation (%RSD) for these parameters
were found within the acceptance criteria of system per-
formance. Higher theoretical plates (21,930) with a lower
%RSD value indicate good separation of TAP on the C18
column in described chromatographic conditions. Tail-
ing factors for most peaks should fall between 0.9 and
1.4, with a value of 1.0 indicating a perfectly symmetrical
peak. Tailing factor for TAP was in between the range;
thus, the TAP's peak was in symmetrical shape. The cap-
acity factor was 16.44 ± 0.222, i.e., TAP has sufficient op-
portunity to interact with the stationary phase resulting
in differential migrations. The co-elution of impurities
or degradants is generally investigated by examining the
peak purity using a PDA detector. Here, the peak purity
at 5.34 min was 1.0; there was no interference with elu-
tion of TAP at retention time, or nothing was co-eluting
along with TAP at 5.34 min. Thus, all system suitability
parameters were within the acceptance criteria.
Linearity and range
Linearity was evaluated by analyzing different concentra-
tions of the standard solutions of the TAP. Response was
a linear function of concentration over the range of 0.2
to 2 μg/ml which was used as the working range of the
method. Peak area and concentration were subjected toTable 1 System suitability parameters for TAP
Parameters Value for TAPa SD %RSD
Number of theoretical plates 21,930 61.64 0.281
Tailing factor 1.12 0.051 0.956
Capacity factor 16.44 0.222 1.352
RT (min) 5.34 0.037 0.698
Peak purity 1.00 0.000 0.000
RT retention time, SD standard deviation, %RSD percentage of relative
standard deviation. aMean of six values.linear least-squares regression analysis to calculate the
calibration equation and correlation coefficient (Table 2).
The linearity of the calibration plots was confirmed by
the high value of correlation coefficients (r2 = 0.9998 ±
0.001), and %RSD for the correlation coefficients was
less than 2.
Accuracy
The accuracy of the method was ascertained by recovery
method. When the method was used for extraction and
subsequent analysis of the drug in the dosage form afterI 0.8 99.75 99.75
II 0.8 100.125 100.125
III 0.8 99.625 99.625
IV 0.8 99.875 99.875
V 0.8 100.125 100.125
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ery was 100.05% (99.7% to 100.9%).
Precision
The repeatability of sample injection and measurement of
peak area were expressed as %RSD (Table 2). Repeatability
and intermediate precision at three different concentra-
tions (0.4, 0.6, and 0.8 μg/ml) for both within-day and
day-to-day analysis were always <2%. These low values of
the %RSD showed that the repeatability and intermediate
precision of the method were within the acceptable value.
Robustness
There was no significant change in the result of developed
method, after the introduction of small deliberate changes
in temperature (±5°C) and formic acid content in aqueous
phase of the mobile phase (±5%). The standard deviation
of peak areas was calculated for each set of conditions and
was found to be <2% (Table 2). The low values of %RSD
indicate that the method is robust.
LOQ and LOD
The developed method was highly sensitive to detect and
determine the TAP content. The LOD for signal-to-noise
ratio of 3:1 was 1 ng/ml (RSD ± 0.067%), and the LOQ for
signal-to-noise ratio of 10:1 was 8 ng/ml (RSD ± 0.063%)
(Table 2).
Specificity
A different set of condition for elution of the TAP was
changed as discussed in previous sections, viz. formic
acid content and temperature; then in spite of these
changes, no additional peak was found, although a very
small change was observed in retention times and peak
shapes. The specificity of the method was ascertained by
analyzing drug standard solution and samples of equiva-
lent concentration (0.8 μg/ml). The identity of the peak in
the sample was confirmed by comparison of the retention
time and UV spectrum of the peak from the sample with
those of the peak from the standard. Peak purity for the
drug was assessed by comparing the UV spectra acquired
at the peak start, peak apex, and peak end. The specificity
of the method was also ascertained by analyzing the
alkaline degraded samples; when degraded sample was
chromatographed, the concentration of the TAP was re-
duced and other peaks were observed at different reten-
tion time.Sample solution stability
The response ratio of all samples was averaged as 184.16
(Table 2). The standard deviation and percentage of rela-
tive standard deviation were found to be less than 2: 1.83
and 0.057, respectively.Analysis of dosage form
TAP is freely water soluble, so drug content from tablet
powder was extracted by triple distilled water. Sonic-
ation of drug powder with triple distilled water has bet-
ter extraction compared to the shaking of solution. TAP
content was determined between 99.79% and 100.33%
with a standard deviation of 0.217. Error of standard de-
viation was far less than the unit which was favorable in
consistency with the result of the method.
Conclusions
Hence, the new liquid chromatographic method in reverse
phase was developed and validated; (Table 3) it was sim-
ple, fast, precise, and accurate without having to use
diethylamine in the mobile phase and with UV detection.
The method was successfully applied to determine the
TAP content in tablet dosage form within acceptable
limits and may be applied for assay, dissolution studies,
bio-equivalence studies, as well as routine analysis in
pharmaceutical industries.
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